Eli Lilly has discontinued a mid-stage clinical trial evaluating bimagrumab—an experimental drug intended to help obesity patients lose fat without sacrificing muscle mass—citing strategic business reasons.

 

The trial, conducted in overweight or obese adults with type 2 diabetes, was testing bimagrumab alone and in combination with Lilly’s obesity drug tirzepatide (marketed under the brand name Zepbound). 

 

Originally designed to monitor not just total weight loss but specifically the balance between fat loss and muscle preservation, the study enrolled about 180 participants and ran for more than a year. The primary endpoint was weight reduction, while muscle versus fat retention was a safety concern. Lilly acquired bimagrumab through its ~$2 billion takeover of biotech firm Versanis. Analysts estimate that “muscle-safe” weight loss therapies could command over $30 billion in sales by 2035. 

 

Notably, Lilly ended the trial only weeks after its initiation (the study began earlier in June and was terminated June 10). However, a parallel study in obese patients without diabetes is still active, with results expected in 2026. Lilly said it routinely reviews its development pipeline to optimize each product’s potential. The company is among several racing to combine appetite-controlling GLP-1 drugs with complementary therapies that reduce muscle loss. 

 

Key Takeaways:

 

Trial halted: Eli Lilly stopped testing bimagrumab in type 2 diabetes patients with obesity.

 

Strategic shift: Decision follows a pipeline review, despite high market potential for muscle-preserving weight loss drugs.

 

Ongoing research: A second trial in obese but non-diabetic patients continues, with results expected in 2026.

 

Big market stakes: Analysts see fat-loss drugs that preserve muscle topping $30 billion in sales by 2035

 

 

Adapted From:

 

https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-halts-trial-experimental-weight-loss-drug-2025-09-25/

11 minutes ago, Bacon1 said:

Eli Lilly has discontinued a mid-stage clinical trial evaluating bimagrumab—an experimental drug intended to help obesity patients lose fat without sacrificing muscle mass—citing strategic business reasons.

Fat people will try anything except exercise and restraint!

9 hours ago, BritManToo said:

Fat people will try anything except exercise and restraint!

 

On one side, I agree with that. 

 

But on my other (wingnut) side, Big Pharma and Big Ag have been adding chemicals to food for years that addict some people to eating more and more of the worst crap. 

 

I've known people who are in literal hunger pain, even when they've just eaten.  That's gotta be miserable.  It doesn't happen to me, but I won't judge them.

On 9/26/2025 at 6:55 AM, BritManToo said:

Fat people will try anything except exercise and restraint!

The customary blanket pejorative generalization.

 

 

15 hours ago, impulse said:

 

On one side, I agree with that. 

 

But on my other (wingnut) side, Big Pharma and Big Ag have been adding chemicals to food for years that addict some people to eating more and more of the worst crap. 

 

I've known people who are in literal hunger pain, even when they've just eaten.  That's gotta be miserable.  It doesn't happen to me, but I won't judge them.

Don’t leave the processed food industries out of the part they play.

 

2 minutes ago, Chomper Higgot said:

Don’t leave the processed food industries out of the part they play.

 

Agreed.

 

I lump them under "Big Pharma" or "Big Ag, depending on where they do what they do to our food supply.